Articles

Inno Pharmaceuticals Completes Nearly RMB 800 Million Series D Funding to Accelerate Global Multicenter Clinical Development of Precision Targeted Drugs

Inno Pharmaceuticals Completes Nearly RMB 800 Million Series D Funding to Accelerate Global Multicenter Clinical Development of Precision Targeted Drugs

The company has pioneered a proprietary active-targeting liposomal drug delivery platform, underpinning an innovative drug pipeline that spans multiple serious disease areas, including cardiovascular and cerebrovascular diseases and glioblastoma.